In ACHIEVE-3, orforglipron outperformed oral semaglutide across the primary and all key secondary endpoints, delivering significantly greater improvements in A1C and weight
proved, through an in vivo study with model rats and an in vitro study using organotypic hippocampal slice cultures, that nicotinamide mononucleotide improved learning and memory in Alzheimers disease rats while also reducing the accumulation of ROS and cell death in organotypic hippocampal slice cultures
Managing Side Effects Based on Dosing Time Gastrointestinal side effects particularly nausea, vomiting, diarrhoea, and constipationare the most commonly reported adverse effects of GLP-1 medications, especially during the initial weeks of treatment or following dose escalation
DNA methylation dysfunction in chronic kidney disease
Many scientists use bacteriostatic water in their experiments